No abstract

Background: Since the efficacy of ranibizumab (RBZ), bevacizumab (BVZ) and aflibercept (AFB) is comparable in neovascular age-related macular degeneration (AMD), we conducted a systematic review and meta-analysis to evaluate the long-term safety profiles of these agents, including ocular safety. Methods: Systematic review identifying randomized controlled trials (RCTs) comparing RBZ, BVZ and AFB directly published before March 2019. Serious ocular adverse events (SOAE) of special interest were endophthalmitis, pseudo-endophthalmitis, retinal pigment epithelium tear and newly identified macular atrophy. Results: Thirteen RCTs selected for meta-analysis (4952 patients, 8723 people-years follow-up): 10 compared RBZ vs. BVZ and three RBZ vs. AFB. There were no significant differences in almost all adverse events (systemic and ocular) between BVZ, RBZ and AFB in up to two years’ follow-up. Macular atrophy was reported heterogeneously and not reported as SOAE in most trials. Conclusions: Direct comparison of RBZ, BVZ and AFB safety profiles in the RCT network meta-analytical setting have not revealed a consistent benefit of these three commonly used anti-vascular endothelial growth factor (anti-VEGF) agents in AMD. Network model ranking highlighted potential benefits of RBZ in terms of a systemic safety profile; however, this appears a hypothesis rather than a conclusion. Newly identified macular atrophy is underestimated in RCTs—future real-world data should be focused on SOAE.

With account to the increase in the elderly population in most of the developed countries, the WHO defines age-related macular degeneration (AMD) as one of the main causes of blindness in the world. A large percentage of disability is accounted for by exudative, or neovascular, form of AMD. Today, a total of 5 anti-VEGF drugs exist that are recommended for treatment of exudative AMD: pegaptanib, ranibizumab, bevacizumab, aflibercept, and conbercept. Despite significant progress in the treatment of neovascular AMD yielded by the introduction into clinical practice of anti-VEGF drugs, some patients report a lack (down to complete lack) of response with standard treatment patterns and even a decrease in treatment efficacy after repeated intravitreal injections.

No abstract

Vascular endothelial growth factor (VEGF) is known as a key mediator of angiogenesis, but there is also evidence of its broad significance in neurogenesis and neuroprotection. Cytokines of the VEGF family affect neovascularization and neural development in the brain, particularly during cerebral ischemia, in which there is a coordinated interaction of angiogenesis and neurogenesis that contributes to rapid functional recovery. This review examines the involvement of VEGF family members and their receptors in physiological and pathophysiological processes as well as the relationship between VEGF-A plasma levels and ischemic stroke.

Проведен анализ современного состояния проблемы классифицирования диабетической ретинопатии, основанный на данных отечественной и мировой литературы в области изучения патогенеза, клинических проявлений, результатов многоцентровых исследований лечения и прогноза данного заболевания. Отмечены ограниченность применения каждой из существующих классификаций, а также попытки объединения и дополнения данных классификаций с целью более полной и детальной диагностики и определения последующих алгоритмов лечения. Как итог, на данный период времени ни одна из существующих классификаций не является состоятельной как в клиническом, так и в практическом аспекте в отношении диабетической ретинопатии.

Возрастная макулярная дегенерация (ВМД) и глаукома в настоящее время в большинстве случаев считаются мультифакториальными заболеваниями, приводящими к развитию необратимой слепоты у пожилых людей в развитых странах. К моногенным формам заболеваний данной группы в настоящее время относится примерно 5%. Изучение молекулярно-генетических аспектов данных видов патологии служит основой для совершенствования диагностических методов, прогнозирования риска развития, течения заболевания и результатов лечения, а также для разработки новых методов терапии. В обзоре объединены современные концепции этиопатогенеза ВМД и глаукомы, описана их взаимосвязь.

No abstract